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Abstract: There is a lack of evidence or societal guidelines regarding the utility of fibrinogen
monitoring during thrombolysis. The purpose of our study was to investigate the current use
of monitoring fibrinogen levels during thrombolysis. A voluntary, anonymous online survey was
sent to all physician members of the Society of Interventional Radiology, consisting of 23 questions
related to practitioner demographics, thrombolysis protocol, and fibrinogen monitoring. There were
455 physician responses; 82% of respondents monitored fibrinogen levels during thrombolysis, of
which 97% decreased or stopped tissue plasminogen activator based on the level. Self-reported
estimates of significant bleeding events during thrombolysis were 1.86% in those who monitored
fibrinogen and 1.93% in those who did not. Only 34% of all respondents report, in their clinical
experience, having found low fibrinogen level to be correlated with bleeding events. There was no
significant difference in self-reported major bleeding rates between practitioners who monitor and
those who do not monitor fibrinogen. This high variability of clinical use of fibrinogen monitoring
during catheter-directed thrombolysis is secondary to the paucity of scientific studies demonstrating
its utility; further scientific investigation is needed to define the true utility of fibrinogen monitoring.
Keywords: thrombolysis; fibrinogen; deep venous thrombosis; tissue plasminogen activator
1. Introduction
Acute thrombosis is a commonly encountered clinical problem associated with high morbidity
and mortality [1]. Potential therapies include systemic anticoagulation, catheter-directed thrombolysis
(CDT), surgical revascularization, and even limb amputation. The choice of therapy depends on the
chronicity of the clot, degree of thrombosis, status of the limb, available resources, and practitioner
preferences. After three randomized multicenter trials published in the 1990s showed clinical efficacy
and safety of CDT, for selected patients, it became the procedure of choice [2–5].
Deep venous thrombosis presents in approximately 100 people per 100,000 [6]. It is associated
with a high rate of both acute and chronic morbidity. Acutely, patients can present with swelling,
pain, or more serious symptoms such as associated pulmonary embolism, phlegmasia cerulean dolens,
or venous gangrene. Long-term sequelae can include debilitating post-thrombotic syndrome (PTS)
or chronic pain and swelling [7]. While a recently completed multicenter randomized control trial
(ATTRACT Trial) failed to show a decrease in the rate of PTS when compared to conservative therapy of
anticoagulation and compression stockings, the severity of PTS was decreased in those who underwent
CDT [8].
Lower extremity arterial lysis is typically reserved for patients with Rutherford Classification I
(viable limb not acutely threatened) and stage IIa (marginally threatened) limbs and has been shown
in these select cases to have equal efficacy compared to surgical revascularization [9].
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Catheter-directed thrombolysis is not without risk. The literature reports an 8.8% risk of major
hemorrhage and a 43.8% risk for minor hemorrhage [10,11]. Patients undergoing catheter-based
thrombolysis require overnight admission with a high level of care, often ICU, to monitor for signs
of bleeding or complications from therapy. In addition to monitoring for clinical signs of bleeding,
laboratory values have been used both to identify occult bleeding (serial hemoglobin and hematocrit)
as well as to predict future bleeding.
Fibrinogen is a soluble circulating glycoprotein and is converted to fibrin by thrombin as part
of the final common pathway in the coagulation cascade. Normal circulating fibrinogen levels range
from 200–400 mg/dL with a half-life of 4 days [12]. Plasminogen is converted into plasmin by tissue
plasminogen activator (TPA), urokinase, factor XIa, and factor XIIa. Plasmin is a proteolytic enzyme
that cleaves the fibrin in thrombi into fibrin degradation products (Figure 1). Fibrinogen levels are
used to predict bleeding during CDT and guide TPA dosing. However, low levels of fibrinogen are
nonspecific and clinical meanings are controversial. It has been associated with both an increased risk
of bleeding as well as prothrombotic conditions [3,13–16]. The purpose of our study was to investigate
the current clinical use of monitoring fibrinogen levels during thrombolysis.
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2. Materials and Methods
A voluntary and anonymous online survey was sent to all physician members of the Society of
Interventional Radiology (n = 3890) after approval by the society. The survey consisted of 23 questions
related to practitioner demographics, thrombolysis protocol, and fibrinogen monitoring (Appendix A).
The survey was available from 10 September 2016 until 20 September 2016. Practice trends were
evaluated. When possible, statistics were performed to evaluate the difference in reported outcomes
between practitioners who monitored fibrinogen and those that did not using the Student’s t-test.
3. Results
There were 455 practitioner responses (11.7%). Two hundred and eighty-three (62.2%) respondents
were in private practice, 156 (34.3%) were in academics, with the remainder in government practices
or multispecialty clinics. The average number of years in practice was 13 years, ranging from <1
to 45 years. The majority of practitioners dedicate >75% of their clinical time doing interventional
radiology (IR) (Figure 2).
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i re 2. erce ta e f ractice t at is i ter e ti al ra i l (I ) f t e res e ts f t e s r e .
Three hundred and seventy-four respondents (82 ; n = 81) onitored fibrinogen during
thro bolysis, and 18 do not onitor fibrinogen. The ost frequent interval for fibrinogen blood
dra s as every 6 h (n = 225; 49.5 ), ranging fro 2 to 24 h (Figure 3).
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Figure 3. Frequency (in hours) with which plasma fibrinogen levels are monitored in those who
routinely monitor during thrombolysis procedures. Q2 = every 2 h, Q3 = every 3 h, Q4 = every 4 h,
Q5 = every 5 h, Q6 = every 6 h, Q8 = every 8 h, Q12 = every 12 h, Q24 = every 24 h.
Adjustment of TPA dose based o fibrinogen levels was variable. Of those that monitored
fibrinogen, 10 es onden s (2.2%) did not d crease the TPA dose based on falling fibrinog , but woul
give cryoprecipitate or fresh frozen p asma (FFP). In the remaining respo d nts who did adjust
based on fibrinogen levels (n = 364), the threshold fibrinogen level that prompted TPA adjustment
varied. The most common level at which TPA was held was at 100 mg/dL (n = 143; 31.4%), with a
range f 40–150 mg/dL. The most common fibrinogen level at which to decrease the dose of TPA
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was 150 mg/dL (n = 105; 23.1%), with a range of 40–300 mg/dL. Twenty-four practitioners (5.3%)
decreased the TPA dose based on a percentage drop from the baseline, rather than an absolute
value. Once TPA was held, there was variability in the protocol for rechecking fibrinogen prior to
restarting thrombolytics, with most restarting between 2 and 6 h (Figure 4). Three practitioners
did not recheck fibrinogen once they stopped thrombolytics, three practitioners performed an
angiogram prior to rechecking fibrinogen, and three practitioners would recheck fibrinogen only
after giving cryoprecipitate.
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Figure 4. Reported protocol for fr itoring fibrinogen levels during thrombolysis.
Q2 = ev ry 2 h, Q3 = ever , 4 = every 4 h, Q5 = every 5 h, Q6 = every 6 h, Q8 = every 8 h,
Q12 = every 12 h, Q24 = every 24 h.
Respondents reported the percentage of their thrombolysis cases (both arterial and venous)
that were complicated by minor bleeding (e.g., oozing from the access site, or blood in stool
without a significant decrease in hematocrit) (Figure 5) and major bleeding (e.g., intracranial
hemorrhage gastrointestinal bleed requiring transfusion/intervention, or retroperitoneal bleed
requiring transfusion or intervention) (Figure 6). Rates of these events did not significantly differ
between those who monitor fibrinogen and those that do not (p = 0.15) (Figure 7). When asked if
in one’s clinical experience they found that low fibrinogen levels to lead to bleeding, 59% (n = 220)
responded that they did not find that low fibrinogen clinically correlated with bleeding.
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Figure 5. Self-reported percentages of cases that are complicated by minor bleeding, such as oozing at
the access site or blood in stool without a significant drop in hematocrit.
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i r 7. Comparison of self-reported percentages of thrombolysis cases that are complicated by major
bleeding complications between practitioners who monitor fibrin gen and those that d not (p = 0.15).
Use of adjunctive systemic anticoagulation during thrombolysis varied. The majority of
practitioners (n = 338; 76%) utilized systemic anticoagulation. The majority used heparin alone
(n = 325; 71.4%) (Table 1). The varied modes of administration of systemic anticoagulation comprised
via a sheath (n = 210), through a peripheral IV (n = 100), through the sheath and peripheral IV (n = 2),
through a peripherally inserted central catheter (PICC; n = 5), or varied practice (n = 14). For those
practitioners who used heparin, the majority used a set dose of 500 units/h (n = 94); however, there
is a broad range of protocols of heparin use, including those that are weight-based, protocol-driven,
or partial thromboplastin time (ptt)-driven (Table 2). The majority of practitioners (n = 374; 82.2%)
monitor hemoglobin and hematocrit levels.
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Table 1. Type of systemic anticoagulation used during thrombolysis.
Type of Anticoagulation Number of Practitioners
Heparin alone 325
Arterial heparin for venous enoxaparin 1
Heparin or, if allergy, argatroban 1
Heparin or lovenox 2
Heparin or bivalirudin 1
Heparin or aggranox 1
Heparin or low-molecular-weight heparin 1
Table 2. Systemic heparin protocol.
Varied: Unspecified 20
Weight-based protocol 21
Protocol-driven
Low dose 12
High dose/therapeutic 4
Partial thromboplastin time
40–45 1
40–50 2
40–60 9
45–65 1
50 1
50–60 4
50–65 1
50–70 2
50–75 1
60 2
>60 1
60–70 1
60–80 5
60–90 1
70–80 1
70–90 1
Set dose in units/h
75 1
100 3
100–500 1
200 8
250 3
300 29
200–300 3
200–400 3
200–600 1
250–500 1
300–500 9
400 30
450 1
400–500 5
400–600 1
400–800 2
400–1500 1
500 94
500–600 4
500–700 2
500–800 3
500–1000 2
600 3
600–800 1
800 3
800–1000 1
1000 8
1000–1200 1
2000 1
2000–5000 1
3000 1
5000 4
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4. Discussion
Both arterial and venous CDT are commonly performed procedures. In addition to the technical
aspects, interventional radiologists play a primary role in patient management. While the potential
benefits of the procedure are big, including limb- or life-saving, a significant risk of this procedure
is bleeding. Fibrinogen is often used as a surrogate to estimate the risk of hemorrhage and guide
TPA dosage to avoid bleeding. Currently, there is a paucity of evidence-based literature or consensus
guidelines to guide the optimal use of fibrinogen in CDT.
Previous studies have reached different conclusions regarding the relationship of fibrinogen levels
and the risk of bleeding. One study reviewed 69 thrombolysis procedures in patients with acute lower
extremity thrombus, with a total of 10 major bleeding events. They showed a significantly higher
rate of bleeding if the fibrinogen level was <150 mg/dL [16]. On the contrary, a study performed by
Lee et al., which examined 49 procedures, found that there was no significant increased risk of bleeding
in patients with fibrinogen levels less than 150 mg/dL, despite larger total doses of TPA and longer
duration of therapy [17]. The prospective PURPOSE trial with 241 patients undergoing catheter-directed
thrombolysis found that there was no statistically significant difference in major or minor bleeding in
patients with fibrinogen >100 mg/dL or <100 mg/dL (p = 0.108) [14]. A meta-analysis found that there
was wide variety in fibrinogen protocols, drawing the conclusion that the value of plasma fibrinogen to
predict hemorrhage in CDT remains unclear [18]. Interestingly, a retrospective review of 32 patients
who underwent catheter-directed thrombolysis found a significant correlation with the percentage of
decrease of fibrinogen and degree of clot burden resolution, suggesting that falling fibrinogen levels
during CDT were associated with efficacy of the procedure and not bleeding risk [19].
The lack of a large prospective randomized trial or consistent results in smaller retrospective
studies is reflected in a 2013 Society of Interventional Radiology consensus statement on Quality
Improvement Guidelines for Percutaneous Management of Acute Lower-Extremity Ischemia from
the Society of Interventional Radiology. In this, it states that given the lack of evidence to show
that laboratory monitoring of fibrinogen will predict adverse bleeding, they neither recommend nor
dissuade its use [20].
Practice patterns found in our survey reflect the inconclusive findings in the literature and the lack
of consensus guidelines. This study showed wide variations on whether fibrinogen was monitored
at all, what fibrinogen level was considered actionable, and what action was taken. Additionally,
our study found no significant difference in self-reported major bleeding events between those who
monitored fibrinogen and those who do not. Potential drawbacks of fibrinogen monitoring include the
laboratory costs, added complexity in patient management, and potential early termination of/decrease
of dose of TPA.
While the findings of our study are limited due to the study design and recall bias, we feel that
this data brings to light the lack of standardization of practice in monitoring of thrombolysis patients.
Further prospective studies are needed to evaluate its efficacy to help standardize practice in the hopes
of improving patient care and safety.
5. Conclusions
There is a paucity of literature to support the common clinical practice of monitoring fibrinogen
levels during thrombolysis and its use as a predictor of patient bleeding. Our study highlighted the
widely varied clinical practice and lack of standardization not only for whether or not to monitor
fibrinogen, but how to respond to different fibrinogen levels. Further research to determine the value
of monitoring fibrinogen is needed.
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Appendix A
1. What type of institution do you practice? What type of institution do you practice?
Private
Academic
Government
Other (please specify)
2. What percentage of your practice is interventional radiology?
0
100
3. How many years have you been practicing?
4. What percent of your thrombolysis cases have been complicated by a major bleed (includes
intracranial hemorrhage, GI bleed or retroperitoneal bleed necessitating transfusion or intervention)?
0–1%
2–4%
4–6%
6–10%
>10%
5. What percent of your thrombolysis cases have been complicated by a minor bleed (includes oozing
at the access site, blood in stool without significant decrease in hematocrit)?
0–5%
5–10%
10–15%
15–20%
>20%
6. In your experience have you found that low fibrinogen levels lead to bleeding?
Yes
No
Other (please specify)
7. Do you draw a pre-thrombolysis fibrinogen level?
Yes
No
8. Do you monitor fibrinogen levels during thrombolysis cases (if yes proceed to question 9, if no
proceed to question 19)?
Yes
No
If you answered yes to question 8 please proceed with question 9. If you answered no please
proceed to question 19
9. How often do you monitor fibrinogen levels?
Q2
Q3
Q4
Q5
Q6
Q12
Other (please specify)
10. Do you change therapy based on the fibrinogen level (if yes proceed to question 11, if no proceed
to question 12)?
Yes
No
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11. If you answered yes to question 10, how do you change your thrombolysis protocol based on the
fibrinogen level?
Stop TPA
Decrease dose of TPA
Other (please specify)
12. At what fibrinogen level do you stop TPA?
13. At what fibrinogen level do you decrease TPA?
14. By how much do you decrease TPA (percent from starting dose)?
15. If you adjust or stop thrombolysis do you recheck fibrinogen level prior to restarting thrombolysis
(if yes proceed to question 16, if no proceed to question 17, if N/A proceed to question 18)?
Yes
No
N/A
16. If you answered yes to question 15 when (how many hours after stopping thrombolysis) do you
recheck the fibrinogen level?
0–1 h
1–2 h
2–4 h
4–6 h
6–8 h
8–12 h
Other (please specify)
17. If you answered no to question 15, when (how many hours) do you restart thrombolysis?
18. When restarting thrombolysis at what percentage of the original dose do you restart?
19. Do you have systemic anticoagulation running during thrombolysis (if yes proceed to question 20,
if no proceed to question 23)?
Yes
No
20. If you answered yes to question 19 what agent is used?
21. If you answered yes to question 19 what dose?
22. If you answered yes to question 19 how is it administered?
Through the sheath
Through a peripheral IV
Subcutaneously
Other (please specify)
23. Do you monitor hematocrit and hemoglobin while doing thrombolysis?
Yes
No
Other (please specify)
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